TBPH

Theravance Biopharma, Inc.

NasdaqGMUSDEQUITY DELAYED

17.01

▲ 0.06 (0.35%)

MARKET · —

Price

Open

16.98

Prev close

16.95

Day high

17.02

Day low

16.96

Volume

716.30K

Market cap

—

P/E (TTM)

—

52W range

13.08 – 21.03

Trailing performance

Price return · vs SPY

Returnvs SPY

+0.24% +1.6%

+0.89% -2.8%

+4.10% +1.0%

-13.48% -24.5%

YTD

-9.09% -21.4%

+27.04% +7.0%

+74.46% +0.3%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

16.95

+0.38% from price

SMA 20

16.91

+0.57% from price

SMA 50

16.90

+0.62% from price

SMA 100

16.69

+1.94% from price

SMA 200

17.25

-1.42% from price

EMA 12

16.95

+0.38% from price

EMA 26

16.91

+0.57% from price

EMA 50

16.85

+0.96% from price

RSI (14)

59.4

Neutral

MACD (12,26,9)

0.03

Hist 0.01

ATR (14)

0.05

0.29% of price

Realised vol 30D

3.4%

Annualised

Bollinger upper

17.00

20, 2σ

Bollinger lower

16.83

20, 2σ

50 / 200 cross

Death

16.90 vs 17.25

Trend bias

Below 200

-1.42%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.55

Less volatile than market

Correlation to SPY

0.16

Largely independent

Realised vol 30D

3.4%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-34.6%

Peak to trough

Max drawdown 5Y

-52.2%

Peak to trough

ATR 14

0.05

0.29% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 17.01

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

TBPH · links out to the publisher

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks Zacks · 11d ago Theravance Biopharma Swings to Net Loss in Q2, Revenue Falls MT Newswires · 12d ago Theravance Bio: Q2 Earnings Snapshot Associated Press · 12d ago Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire · 12d ago electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates Zacks · 16d ago Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results GlobeNewswire · 16d ago Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates Zacks · 19d ago Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates Zacks · 23d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.